Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R2 | Q9NPC1 | 13/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 9/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786 | 0.87 | LTB4R2 (0.63) | LTB4R2AGTR1 | |
| SCHEMBL2785 | 0.87 | LTB4R2 (0.63) | LTB4R2AGTR1 | |
| SCHEMBL3055 | 0.87 | LTB4R2 (0.47) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL2721 | 0.77 | BDKRB1 (0.39) | — | |
| SCHEMBL2970 | 0.77 | BDKRB1 (0.39) | — | |
| SCHEMBL2746 | 0.75 | AGTR1 (0.53) | LTB4R2AGTR1ABCB11GP6 | |
| SCHEMBL2394 | 0.73 | LTB4R2 (0.75) | LTB4R2AGTR1 | |
| SCHEMBL2395 | 0.73 | LTB4R2 (0.75) | LTB4R2AGTR1 | |
| SCHEMBL8475874 | 0.70 | LTB4R2 (0.71) | LTB4R2AGTR1 | |
| SCHEMBL2126 | 0.69 | SCN1A (0.48) | LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5965592-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1999-10-12 | — | — | US | disclosed |
| EP-0443983-B1 | Acyl compounds | CIBA GEIGY AG (CH) | 1996-02-28 | — | — | EP | disclosed |
| US-5399578-A | Hypotensive; valsartan; high blood pressure and cardiac insufficiency | CIBA-GEIGY CORP (US) | 1995-03-21 | — | — | US | disclosed |
| EP-0443983-A1 | Acyl compounds | CIBA-GEIGY AG (CH) | 1991-08-28 | — | — | EP | disclosed |